Rachel Abbott joined Pan Cancer T in January 2023 as Chief Scientific Officer, before stepping up to become CEO in May 2023.
Rachel started her biotech career as a scientist at Adaptimmune and grew into managerial roles where she oversaw the discovery of novel TCRs through T cell cloning, pipeline testing of affinity-enhanced TCRs, and manufacturing large-scale T cells for use in preclinical packages. Rachel led the pipeline project for the development of a T cell therapy directed to PRAME and managed pre-IND safety and efficacy data packages for two next-generation NY-ESO targeting T cell products, all in partnership with GSK.
Prior to joining Pan Cancer T, Rachel served as Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio. In this role, she was responsible for strategic frameworks within research focusing on the discovery and validation of dark antigens and the identification of dark antigen-specific TCRs.
Rachel holds a DPhil and an MBiochem in Molecular and Cellular Biochemistry from the University of Oxford. She was a post-doctoral Research Fellow at the University of Birmingham for seven years studying T-cell responses to Epstein-Barr virus.